Pacific BiosciencesPACB
PACB
About: Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Employees: 575
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
148% more call options, than puts
Call options by funds: $4.29M | Put options by funds: $1.73M
3% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 35
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
1% less funds holding
Funds holding: 225 [Q4 2024] → 222 (-3) [Q1 2025]
19.2% less ownership
Funds ownership: 94.77% [Q4 2024] → 75.57% (-19.2%) [Q1 2025]
22% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 73
44% less capital invested
Capital invested by funds: $475M [Q4 2024] → $265M (-$210M) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1.25
4%
upside
Avg. target
$2.01
68%
upside
High target
$3
150%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Piper Sandler David Westenberg | 4%upside $1.25 | Neutral Maintained | 15 May 2025 |
Stephens & Co. Mason Carrico | 50%upside $1.80 | Overweight Reiterated | 15 May 2025 |
Canaccord Genuity Kyle Mikson | 150%upside $3 | Buy Maintained | 10 Apr 2025 |
Scotiabank Sung Ji Nam | 67%upside $2 | Sector Outperform Maintained | 25 Mar 2025 |
Financial journalist opinion
Based on 5 articles about PACB published over the past 30 days
Positive
Zacks Investment Research
2 days ago
Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know
Pacific Biosciences of California (PACB) closed at $1.18 in the latest trading session, marking a +1.72% move from the prior day.
Positive
Zacks Investment Research
1 week ago
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.
Neutral
PRNewsWire
1 week ago
Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date
Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide NEW YORK and MENLO PARK, Calif. , June 2, 2025 /PRNewswire/ -- Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long read sequencing platforms, to launch the largest global whole genome sequencing initiative for ALS to date.
Positive
Zacks Investment Research
2 weeks ago
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Zacks Investment Research
3 weeks ago
PacBio Stock Slips Despite New China Distribution Deal With Haorui
PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.
Positive
Zacks Investment Research
1 month ago
PACB Stock May Rise Following the Deal With Chulalongkorn University
PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand.
Neutral
GlobeNewsWire
1 month ago
PacBio Board Independent Investigation Concludes Allegations Unsubstantiated
MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the “Special Committee”) has concluded its independent investigation into previously disclosed allegations from an attorney representing an employee impacted by our recent reduction in force regarding certain employment practices and cybersecurity matters of the Company. The allegations did not involve the current, or any previously reported, financial results, and the investigation found no improper employment practices and no material inaccuracies or omissions with respect to the cybersecurity disclosures in the Company's 2024 Form 10-K.
Negative
Zacks Investment Research
1 month ago
PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates
Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system shipments.
Neutral
Zacks Investment Research
1 month ago
Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Neutral
Seeking Alpha
1 month ago
Pacific Biosciences of California, Inc. (PACB) Q1 2025 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance & Investor Relations Christian Henry - President & Chief Executive Officer Jim Gibson - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research David Westenberg - Piper Sandler William Ruby - TD Cowen Operator Good afternoon, everyone. And welcome to the PacBio First Quarter 2025 Earnings Conference Call.
Charts implemented using Lightweight Charts™